Addex Therapeutics
ADXN
2 hedge funds and large institutions have $19.7K invested in Addex Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
295% more capital invested
Capital invested by funds: $4.99K → $19.7K (+$14.7K)
100% more funds holding
Funds holding: 1 → 2 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$18.5K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.28K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $12.3K | +$18.5K | +1,500 | New |
|
|
ACM
2
ADAR1 Capital Management
Austin,
Texas
| $7.4K | +$6.28K | +510 | +131% |
|
ADXN Hedge Fund Activity: Q2 2024 in Review
2 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q2 2024, worth a combined $19.7K — up 295% from $4.99K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ADXN positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $18.5K.
- 2 institutional investors held Addex Therapeutics (ADXN) as of Q2 2024, up from 1 in Q1 2024.
- Funds reported $19.7K of Addex Therapeutics stock for Q2 2024, up 295% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q2 2024 and 0 closed out, a net change of +1 holder.
- The largest Addex Therapeutics buyer in Q2 2024 was Morgan Stanley, an estimated $18.5K added.
Based on aggregated 13F filings for Q2 2024.